Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 6/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CTRC | Q99895 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11261922 | 1.00 | MIF (0.49) | MIFMAOBPTPN1MAOAFTO | |
| SCHEMBL23356548 | 0.75 | MAOB (0.40) | MIFMAOBPTPN1MAOAFTO | |
| SCHEMBL11663324 | 0.73 | AR (0.43) | MIFMAOBMAOAFTOKDM4E | |
| SCHEMBL2490828 | 0.71 | CHRM2 (0.50) | MIFMAOBPTPN1MAOAFTO | |
| SCHEMBL7507706 | 0.69 | MIF (0.46) | MIFMAOBPTPN1MAOAFTO | |
| SCHEMBL1310425 | 0.69 | PIN1 (0.56) | MIFMAOBPTPN1MAOAFTO | |
| SCHEMBL25567373 | 0.68 | GSK3B (0.49) | MIFMAOBPTPN1MAOAFTO | |
| SCHEMBL23300745 | 0.68 | PTPN1 (0.46) | MIFMAOBPTPN1MAOAPTPN2 | |
| Isoflavone SCHEMBL8028 | 0.67 | ALDH1A1 (0.66) | MIFMAOBPTPN1MAOANISCH | |
| SCHEMBL19180204 | 0.67 | MIF (0.44) | MIFMAOBPTPN1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220305147-A1 | SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | VYRIPHARM ENTERPRISES, INC. | 2022-09-29 | — | — | US | claimed |
| EP-4514340-A1 | TREATMENT OF THE ADVERSE CARDIOVASCULAR EFFECTS OF CANNABINOIDS | Greenstone Biosciences, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023212130-A1 | TREATMENT OF THE ADVERSE CARDIOVASCULAR EFFECTS OF CANNABINOIDS | GreenStone Biosciences, Inc. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20220305147-A1 | SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | VYRIPHARM ENTERPRISES, INC. | 2022-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220305147-A1 | SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | CNR2, CNR1, FAAH | MIF 4364/4885MAOB 2801/4885PTPN1 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.